Adjunctive moxibustion treatment for tuberculosis: A randomised clinical trial investigating potential efficacy and comparative safety

Show simple item record

dc.contributor.author Ibanda, Hood Ahmed
dc.contributor.author Mubiru, Frank
dc.contributor.author Musiba, Rogers
dc.contributor.author Itaya, Sachiko
dc.contributor.author Craig, Jenny
dc.contributor.author Young, Merlin
dc.contributor.author Waako, Paul
dc.date.accessioned 2019-10-14T15:02:17Z
dc.date.available 2019-10-14T15:02:17Z
dc.date.issued 2018
dc.identifier.issn 1876-3839
dc.identifier.uri https://doi.org/10.60682/vcwn-t702
dc.description.abstract Introduction Small cone direct moxibustion (‘moxa’) is known to have been used in Japan at the height of its tuberculosis (TB) epidemic in the pre-antibiotic era with documented reports of efficacy including one scientific animal study. Antimicrobial resistant (AMR) disease is becoming a major threat to global health with drug-resistant TB the largest component of this threat, most particularly in Africa and Asia. This study comprises the first scientific investigation into whether this simple traditional therapy might help the challenge of reducing the persistent burden of TB in middle- and low-income countries. Methods 180 newly diagnosed TB patients were randomly assigned to two groups, one given standard first line ‘Directly Observed Treatment, Shortcourse’ (DOTS) TB drug therapy, and the other first line DOTS along with daily self-administered moxibustion. The two groups were carefully monitored for differences in recovery rates and serological and immunological markers were compared. Results The moxa group responded to the drug therapy faster than the group receiving standard TB therapy as measured by their becoming sputum negative (P = 0.032 in the first month). There were accompanying improved haemoglobin levels of statistical significance (P = 0.003) with the same P value seen in a sub-group of TB patients who were also HIV positive. It was also noted that the moxa patients reported statistically significant better adherence to their drug therapy (P = 0.001). Conclusions The results demonstrate positive effects of moxa treatment on both reduced infectivity and drug adherence including in HIV co-infected cases. Despite previous reports of a wider range of haematological effects, these were limited to an increase in haemoglobin. There was no evidence that moxa use led to improvements in patients’ well-being, contrary to previous anecdotal evidence. The paper concludes that more investigations should be developed to provide a broader understanding of both effect and potential benefit of moxa therapy in treating human pulmonary TB disease (both with and without co-infection with HIV). It further recommends that these should include MDR-, XDR-, (multi-drug resistant and extensively-drug resistant) and programmatically-untreatable TB (including in palliative care scenarios). en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.subject Moxibustion en_US
dc.subject Tuberculosis en_US
dc.subject HIV en_US
dc.subject MDR-TB en_US
dc.subject Immuno-modulation en_US
dc.subject Immunotherapy en_US
dc.subject Randomised control trial en_US
dc.title Adjunctive moxibustion treatment for tuberculosis: A randomised clinical trial investigating potential efficacy and comparative safety en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search BUOADIR


Browse

My Account